Phase 2Active, not recruiting
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
- Sponsor
- Montefiore Medical Center (Academic or other)
- Enrolment
- 17 enrolled
- Conditions
- Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
- Interventions
- Nivolumab; (8gy x 3); Platinum Doublet
- Ages
- adults, older adults
- Registry
- NCT05500092
From the registry
An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer
Primary outcomes
- Complete Pathological Response